Early and reliable detection of diseases is the basis for a healthy and long life.
xken health is based on the research of the mosaiques Group, founded in Hanover in 2002. The group's goal is to conduct biotechnological research at the highest scientific and clinical standards for the benefit of its customers. It is an international market leader in the field of clinical proteomic analysis. The company's research and product development focuses on the practical implementation of clinical proteomic analysis, the foundation of personalized medicine. Mosaiques collaborates with numerous renowned clinics and institutes worldwide.Prof. Dr. Harald Mischakis the company founder and a member of the management board.
>20 years
Research
>400
scientific publications
>100
clinical trials
Milestones from 20 years of research
Serviceliste
-
2002Listenelement 1This year, the coupling of capillary electrophoresis with mass spectrometry was successfully achieved. The mosaiques group was founded.
-
2003Listenelement 2It is shown for the first time that the determination of proteins and peptides in human urine using capillary electrophoresis mass spectrometry is a suitable tool for establishing new diagnostic markers.
-
2005Listenelement 3A scientific study is published demonstrating the significant stability advantage of urine over blood plasma. Mosaiques applies statistical methods and artificial intelligence to extract and process the relevant information from the multidimensional proteomic data.
-
2006Listenelement 4Further research reveals the first disease markers for prostate cancer and bladder cancer.
-
2008First positive study results on the early detection of heart and kidney diseases are published.
-
2009Initial study results suggest an association between age and kidney disease.
-
2010Recommendations and guidelines for the identification and qualification of biomarkers in clinical proteomic analysis are defined and published.
-
2012The validity of clinical proteomic analysis is established in the context of heart failure.
-
2014The world's first proteome-driven randomized multicenter clinical intervention trial is launched.
-
2016The American Food and Drug Administration (FDA) has issued Prof. Dr. Harald Mischak a letter of support for the use of clinical proteomic analysis in pharmaceutical studies.
-
2017Another breakthrough has been achieved: Proteomic analysis can be used to distinguish between different kidney diseases.
-
2018Proteomic analysis can detect a predisposition to cancer at an early stage.
-
2020The first prospective intervention study is published in which therapy was initiated through early detection of diabetic kidney disease using clinical proteomic analysis.
-
2021Biological age can be determined using clinical proteomic analysis and the dynamics of aging can be predicted.
-
2022By combining various tests and approaches, a holistic health assessment is created. Thus, xken health – the health test – was born.
-
2023A method for prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney diseases was developed.
